(PYPD) PolyPid Ltd. Business Model Canvas Research

Academic surgeons and key opinion leaders help PolyPid Ltd win trust in operating rooms by shaping trial design, publishing evidence, and teaching clinicians. That matters because surgical site infections affect about 2% to 5% of operated patients, so KOL endorsement can speed use of SSI-prevention products in cardiothoracic and other high-risk surgeries.

• KOLs boost clinical adoption.
• They guide evidence and education.
• SSI risk makes endorsement critical.

PolyPid Ltd. may rely on regional distributors or licensing partners to launch D-PLEX100, which lets it reach more markets without building a global sales force. That model fits advanced-stage specialty biopharma, where one partner can cover multiple territories and cut launch costs.

It also keeps fixed SG&A lean; many small biopharma firms run with under 100 commercial staff before partnering.

• Extends market access fast
• Lowers sales-force capex
• Fits specialty biopharma launches

PolyPid’s regulatory submission work covers dossiers, safety packages, and CMC quality files, which are needed for product approval and label claims. This work stays active in late development, since even one label change or data update can trigger new agency questions and extra documentation.

It is a high-stakes, low-margin activity: missed filings can delay approval and push back revenue, while strong submission quality helps shorten review cycles.

• Builds approval dossiers
• Supports labeling decisions
• Runs through late development
• Reduces filing risk

PolyPid Ltd. must map market access, pricing, and hospital adoption before D-PLEX100 can scale. In U.S. launch planning, the U.S. hospital market has over 6,000 hospitals, so medical affairs and post-launch evidence will matter for guideline fit and payer pull.

• Price for hospital budgets
• Prove outcomes post-launch
• Win formulary access fast

PolyPid Ltd.’s scientific and regulatory team is a core asset in its narrow-asset model: one lead asset means every choice in drug development, CMC, clinical operations, and regulatory affairs can change cost, timing, and approval odds. Specialized human capital helps cut development risk and speed the path to market, which matters more when the company is focused on a single pipeline.

• Drug development expertise
• CMC control
• Clinical ops execution
• Regulatory speed

PolyPid Ltd.’s patent portfolio protects the platform and extends product life cycle, which matters most before commercial launch when IP can shape market entry and pricing power. Strong patent coverage also helps defend against copycats and can lift partnering value in talks with pharma partners.

• Protects core platform IP
• Supports pre-launch partnering
• Defends against competitors
• Extends product lifecycle

Lower downstream care burden means fewer SSIs, which can cut readmissions, reoperations, and length of stay. CDC data still puts SSI risk at 2%-5% of surgical patients, and each infection can add about 7-11 hospital days and $10,000-$25,000 in extra cost.

• Fewer SSIs mean fewer readmissions
• Lower reoperation and LOS costs
• Hospitals and payers avoid waste

PLEX is PolyPid Ltd.’s proprietary controlled-release platform, designed to deliver drug locally at the site of surgery instead of relying on standard systemic therapy. That gives PolyPid a differentiated asset base, with platform reuse that can support future pipeline expansion beyond a single product story.

• Local delivery vs standard therapy
• Platform can extend to new programs
• Reduces single-asset dependence

PolyPid Ltd. must keep close ties with investigators and study coordinators so trial execution stays clean, data quality stays high, and publication output keeps flowing. In this model, evidence generation is not just R&D; it is part of the customer relationship itself, because strong site support drives faster enrollment, better protocol adherence, and more credible clinical data.

• Keep investigators engaged
• Support study coordinators daily
• Protect trial quality
• Raise publication output
• Turn evidence into trust

PolyPid Ltd.’s partner-based account management fits a regional licensing model, where partners handle support, supply, and compliance while the Company keeps a lean internal team. That structure can widen market reach without adding much headcount, which matters for a biotech still scaling its commercial footprint.

• Partner-led support and compliance
• Lower internal headcount burden
• Better regional reach

Licensing partners let PolyPid Ltd. reach markets it does not cover directly, while the partner handles local registration, marketing, and distribution. For a small specialty pharma company, that can cut upfront market-entry cost and speed launch in new geographies much faster than building a full local team.

• Local regulatory filing support
• Built-in sales and distribution reach
• Faster geographic expansion

Medical conferences and peer-reviewed publications are a core channel for PolyPid Ltd. because surgeons adopt new products faster when they see clinical data, trial design, and real-world outcomes. In biopharma, evidence-backed dissemination is often the gate to trust; PolyPid’s D-PLEX100 was studied in the 455-patient SHIELD phase 3 program, giving congress talks and journal papers direct commercial value.

• Build surgeon awareness with data
• Use journals to add credibility
• Turn clinical evidence into adoption

Payers and health systems are key buyers because they control reimbursement and judge SSI prevention on total cost, not just product price. SSIs can add about $3.3 billion to $10 billion in annual U.S. hospital costs and extend stays by 7 to 11 days, so PolyPid Ltd. must prove lower total care cost and fewer downstream claims.

• Reimbursement drives access
• Cost avoidance is the core case
• Total care cost must fall

Commercial partners are secondary customers for PolyPid Ltd., mainly regional pharma partners and distributors that may buy rights, supply access, or territory deals. This channel matters more as PolyPid scales beyond its core focus on 1 lead asset, D-PLEX100, and needs local reach for wider commercial rollout.

• Regional partners buy rights or territory access
• Distributors add local market reach
• Value rises as expansion widens

Regulatory and legal costs stay recurring for PolyPid Ltd. because SEC filings, FDA-linked compliance, patent maintenance, and outside counsel are needed to protect the company’s IP and keep approval work moving. For an IP-driven biopharma firm, these costs can run into the high six figures or more each year as patent portfolios expand and filings stack up.

• Recurring filings and compliance fees
• Patent maintenance and prosecution costs
• Outside counsel for approval work
• Protects IP and regulatory path

PolyPid Ltd. is still in the pre-revenue buildout stage, so SG&A covers general administration, medical affairs, and launch prep that lift overhead before first sales. As the commercial team, systems, and field support scale, these costs usually jump ahead of revenue; in 2025, that meant higher operating spend versus no product sales yet.

• Admin and medical affairs add fixed overhead.
• Commercial build-out raises staff and systems costs.
• Launch prep often peaks before first revenue.

PolyPid Ltd. has reported 0 royalty revenue in its latest filings, so any regional out-licensing would add a new, high-margin stream tied to net sales. Royalties fit a lean model: they scale with product demand, but need far less capex than building a full commercial team.

• 0 royalty revenue reported
• Scales with net sales
• Low capex, lean model

PolyPid Ltd. can book collaboration fees and product supply income while its lead assets are still in development, but these lines are usually much smaller than future product sales. For a late-stage biotech, this kind of revenue helps offset R&D burn and smooths cash flow before commercialization.

• Supports cash flow before launch
• Usually smaller than product sales
• Often tied to supply agreements